A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy

Goemans, N.; Mercuri, E.; Belousova, E.; Komaki, H.; Dubrovsky, A.; McDonald, C.M.; ... ; DEMAND III Study Grp (2018)

Article / Letter to editor

• Duchenne muscular dystrophy
• Drisapersen
• Dystrophin
• Antisense oligonucleotide
• Exon skipping
• six-minute walking distance

• All authors: Goemans, N.; Mercuri, E.; Belousova, E.; Komaki, H.; Dubrovsky, A.; McDonald, C.M.; Kraus, J.E.; Lourbakos, A.; Lin, Z.N.; Campion, G.; Wang, S.X.; Campbell, C.; DEMAND III Study Grp
• Date: 2018-01-31
• Journal: Neuromuscular Disorders
• Volume: 28
• Issue: 1
• Pages: 4 - 15
• DOI: doi:10.1016/j.nmd.2017.10.004